It is not a coincidence that the guideline update for biomarkers suggested that testing for PIK3CA mutations should use samples from tumor tissue or ctDNA in plasma to determine eligibility for treatment with alpelisib plus fulvestrant, a selective estrogen receptor degrader. The gene discussed is PIK3CA; the disease is neoplasm.